CTAD Highlights November 5, 2015 
CTAD Highlights November 6, 2015
AEROBIC EXERCISE MAY REVERSE AGING EFFECTS ON THE BRAIN
EMERGING INTEREST IN NEUROINFLAMMATION AS A TREATMENT TARGET FOR ALZHEIMER’S DISEASE
INCREASING VALUE AND REDUCING WASTE IN ALZHEIMER’S DISEASE CLINICAL RESEARCH
Complilation of AlzForum coverage
In the spotlight
CTAD Looks Ahead to 2015
The seventh conference on Clinical Trials on Alzheimer's Disease in Philadelphia last month covered everything from a sprinkling of new trial results to a new focus on tau PET imaging to a plea from former FDA honcho Rusty Katz that trialists stop obsessing over disease modification and aggressively pursue big therapeutic effects instead. Madolyn Rogers and Gabrielle Strobel close out their report on the meeting with a look at the role brain amyloid plays in AD, and a review of what new treatments may be in store for 2015.
- Large Studies Agree: Brain Amyloid Accelerates Cognitive Decline
- New Treatments for Alzheimer's Behavioral Symptoms on Horizon
- New Ideas for Alzheimer's Treatment: What's on Offer in 2015?
- Just for Her? Study of Women's Biology Offers New Therapeutic Angle
- Try This at Home: Cognitive Testing in the Age of Prevention Trials?
- New Target Has Legs: Tau PET, Mice, and Antibodies
- Immunotherapy II: Active Approaches Down, New Passive Crops Up
- Immunotherapy I: Baby Steps, but No Breakthroughs
- From Shared CAP, Secondary Prevention Trials Are Off and Running
- Rusty Unleashed: Forget Disease Modification, Go for Big Effect
- CTAD Shows Alzheimer's Field Trying to Reinvent Itself
ctad@ant-congres.com
